JAMA:多塞平漱口液或苯海拉明利多卡因抗酸漱口液用于患者放疗导致的口腔疼痛

2019-04-18 MedSci MedSci原创

研究认为,在接受头颈部放射治疗的患者中,多塞平漱口液或苯海拉明利多卡因抗酸漱口液可减少患者口腔粘膜炎疼痛,但与安慰剂相比,效果不显著

口腔黏膜炎在头颈癌放疗期间较为普遍。近日研究人员比较了多虑平漱口水与苯海拉明-利多卡因抗酸漱口水治疗口腔黏膜炎相关疼痛的疗效。

本次研究为III期临床研究,275名头颈部放疗患者参与,口腔粘膜炎疼痛评分为4分或更高(评分为0-10),并进行了最多28天的随访。92名患者接受多塞平漱口液(25 mg/5ml)、91名患者接受苯海拉明-利多卡因-抗酸组,92名名患者接受安慰剂。研究的主要终点是单剂量多西平漱口液或苯海拉明利多卡因抗酸漱口液与单剂量安慰剂相比4小时内的口腔黏膜炎总疼痛减轻程度(由曲线下面积定义,并根据基线疼痛评分进行调整)。次要终点包括困倦、异味、刺痛或灼伤。患者平均年龄61岁,女性占21%,227名(83%)完成了各项方案的治疗。多塞平漱口液组前4小时粘膜炎疼痛减少11.6分,苯海拉明-利多卡因-抗酸漱口水组前4小时粘膜炎疼痛减少11.7分,安慰剂组减少8.7分。多塞平漱口液组与安慰剂组的组间差异为2.9分,苯海拉明-利多卡因-抗酸漱口液组与安慰剂组的组间差异为3.0分。多塞平漱口液组与安慰剂组相比,患者嗜睡、异味、针刺或灼伤等不良事件发生率更高。多塞平漱口液组的3级以上不良事件有3例(4%),苯海拉明-利多卡因-抗酸漱口液组3例(4%),安慰剂2例(2%)。多塞平漱口液组有5名患者(6%)出现疲劳,苯海拉明利多卡因抗酸漱口液组无患者出现疲劳。

研究认为,在接受头颈部放射治疗的患者中,多塞平漱口液或苯海拉明利多卡因抗酸漱口液可减少患者口腔粘膜炎疼痛,但与安慰剂相比,效果不显著。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1662706, encodeId=60411662e0694, content=<a href='/topic/show?id=189c431e791' target=_blank style='color:#2F92EE;'>#多塞平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43177, encryptionId=189c431e791, topicName=多塞平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ff25457955, createdName=124987a0m74(暂无昵称), createdTime=Thu Aug 08 14:25:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976112, encodeId=ce0119e61129f, content=<a href='/topic/show?id=37f466661b7' target=_blank style='color:#2F92EE;'>#漱口液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66661, encryptionId=37f466661b7, topicName=漱口液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Dec 25 14:25:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369296, encodeId=9b01369296a3, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 08 16:43:05 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288850, encodeId=4e051288850a9, content=<a href='/topic/show?id=0b1e322e85e' target=_blank style='color:#2F92EE;'>#利多卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32278, encryptionId=0b1e322e85e, topicName=利多卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Fri Apr 19 21:25:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364838, encodeId=2f6236483808, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Thu Apr 18 11:27:16 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1662706, encodeId=60411662e0694, content=<a href='/topic/show?id=189c431e791' target=_blank style='color:#2F92EE;'>#多塞平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43177, encryptionId=189c431e791, topicName=多塞平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ff25457955, createdName=124987a0m74(暂无昵称), createdTime=Thu Aug 08 14:25:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976112, encodeId=ce0119e61129f, content=<a href='/topic/show?id=37f466661b7' target=_blank style='color:#2F92EE;'>#漱口液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66661, encryptionId=37f466661b7, topicName=漱口液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Dec 25 14:25:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369296, encodeId=9b01369296a3, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 08 16:43:05 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288850, encodeId=4e051288850a9, content=<a href='/topic/show?id=0b1e322e85e' target=_blank style='color:#2F92EE;'>#利多卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32278, encryptionId=0b1e322e85e, topicName=利多卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Fri Apr 19 21:25:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364838, encodeId=2f6236483808, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Thu Apr 18 11:27:16 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
    2019-12-25 drwjr
  3. [GetPortalCommentsPageByObjectIdResponse(id=1662706, encodeId=60411662e0694, content=<a href='/topic/show?id=189c431e791' target=_blank style='color:#2F92EE;'>#多塞平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43177, encryptionId=189c431e791, topicName=多塞平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ff25457955, createdName=124987a0m74(暂无昵称), createdTime=Thu Aug 08 14:25:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976112, encodeId=ce0119e61129f, content=<a href='/topic/show?id=37f466661b7' target=_blank style='color:#2F92EE;'>#漱口液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66661, encryptionId=37f466661b7, topicName=漱口液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Dec 25 14:25:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369296, encodeId=9b01369296a3, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 08 16:43:05 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288850, encodeId=4e051288850a9, content=<a href='/topic/show?id=0b1e322e85e' target=_blank style='color:#2F92EE;'>#利多卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32278, encryptionId=0b1e322e85e, topicName=利多卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Fri Apr 19 21:25:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364838, encodeId=2f6236483808, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Thu Apr 18 11:27:16 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
    2019-07-08 小微940490

    mark

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1662706, encodeId=60411662e0694, content=<a href='/topic/show?id=189c431e791' target=_blank style='color:#2F92EE;'>#多塞平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43177, encryptionId=189c431e791, topicName=多塞平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ff25457955, createdName=124987a0m74(暂无昵称), createdTime=Thu Aug 08 14:25:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976112, encodeId=ce0119e61129f, content=<a href='/topic/show?id=37f466661b7' target=_blank style='color:#2F92EE;'>#漱口液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66661, encryptionId=37f466661b7, topicName=漱口液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Dec 25 14:25:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369296, encodeId=9b01369296a3, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 08 16:43:05 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288850, encodeId=4e051288850a9, content=<a href='/topic/show?id=0b1e322e85e' target=_blank style='color:#2F92EE;'>#利多卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32278, encryptionId=0b1e322e85e, topicName=利多卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Fri Apr 19 21:25:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364838, encodeId=2f6236483808, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Thu Apr 18 11:27:16 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1662706, encodeId=60411662e0694, content=<a href='/topic/show?id=189c431e791' target=_blank style='color:#2F92EE;'>#多塞平#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43177, encryptionId=189c431e791, topicName=多塞平)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10ff25457955, createdName=124987a0m74(暂无昵称), createdTime=Thu Aug 08 14:25:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1976112, encodeId=ce0119e61129f, content=<a href='/topic/show?id=37f466661b7' target=_blank style='color:#2F92EE;'>#漱口液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66661, encryptionId=37f466661b7, topicName=漱口液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Wed Dec 25 14:25:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369296, encodeId=9b01369296a3, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Mon Jul 08 16:43:05 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288850, encodeId=4e051288850a9, content=<a href='/topic/show?id=0b1e322e85e' target=_blank style='color:#2F92EE;'>#利多卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32278, encryptionId=0b1e322e85e, topicName=利多卡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c982214, createdName=tomyang86, createdTime=Fri Apr 19 21:25:00 CST 2019, time=2019-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364838, encodeId=2f6236483808, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Thu Apr 18 11:27:16 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
    2019-04-18 183****7028

    学习

    0

相关资讯

肿瘤患者放化疗后口腔粘膜炎的处理

肿瘤化疗和放疗过程中都可能对快速增长的黏膜上皮细胞造成损伤,引发口腔黏膜炎和胃肠道黏膜炎。放化疗后口腔黏膜炎是指由于放射线电离辐射损伤或者化疗药物的应用引起免疫力下降,口腔内菌群失调,导致口腔软组织发生炎症病变,是肿瘤患者接受化疗过程中较常见,最痛苦的毒副作用之一。粘膜炎一般具有自愈性,一旦组织不受损伤,就开始愈合。黏膜损伤会在几天内自然地消失,一般在化疗后10~14天内完全愈合。

新型口服液episil在国内获批,用于治疗放化疗引起的口腔黏膜炎

日本Solasia Pharma KK公司宣布其episil口服液已获得国家食品药品监督管理局(NMPA)的批准,用于缓解化疗/或放疗引起的口腔粘膜炎(OM)。作为缓解口腔粘膜炎的唯一即用型医疗设备,episil将为国内口腔粘膜炎患者提供新的治疗选择,特别是对于接受放疗/或化疗后的癌症患者。